Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995405 | 0.86 | SIGMAR1 (0.66) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL11172523 | 0.83 | SIGMAR1 (0.62) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL9373661 | 0.82 | KDM4E (0.71) | SIGMAR1DRD2KCNH2HTR1AKDM4E | |
| SCHEMBL14440408 | 0.80 | KCNH2 (0.69) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL9041083 | 0.80 | KCNH2 (0.80) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL6221057 | 0.79 | KCNH2 (0.62) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL14440410 | 0.79 | KCNH2 (0.72) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| Hydrochloric Acid SCHEMBL6217938 | 0.78 | KCNH2 (0.61) | SIGMAR1DRD2KCNH2CYP2D6HTR1A | |
| SCHEMBL9944698 | 0.78 | ALOX15 (0.41) | ALDH1A1 | |
| SCHEMBL1820012 | 0.77 | ALDH1A1 (0.59) | SIGMAR1DRD2CHRNA7KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | SIGMAR1 3622/4885DRD2 4574/4885KCNH2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.